Call Us : +603-9010-3058
Email Us : This email address is being protected from spambots. You need JavaScript enabled to view it.

You are here: Home Publications, News & Events News & Events - English The Star : HITV in fight against cancer

Sunday17 February 2019

The Star : HITV in fight against cancer


This innovation in cancer treatment is relatively new, but the results have been encouraging, and trials at the UKM Medical Centre using HITV to fight cancer are in progress.

A FORM of immunotherapy is showing encouraging results in the treatment of stage 4 and recurrent cancer patients.

In a public forum held last Sunday at the Kuala Lumpur Convention Centre, Dr Kenichiro Hasumi, founder of Hasumi International Research Foundation and innovator of the Hasumi Immuno-Therapeutic Vaccine (HITV), shared his clinical findings on the effects of HITV on patients with stage 4 or recurrent cancer.

He reported that the HITV protocol managed to achieve 80% complete regression in stage 4 cancer patients who fulfilled treatment criteria, i.e. not more than 10 metastatic tumours, with each tumour not more than 5cm in size.

The main thrust of HITV therapy is the use of dendritic cells to prime cancer cells to be vulnerable to subsequent treatment procedures.

Dendritic cells are a critical link in the immune system. Acting as sentinels, these cells “patrol” the body seeking out foreign invaders, whether these be bacteria, viruses or cancer cells.

After “capturing” the invaders, dendritic cells “cut” them into smaller pieces and display the antigenic fragments on their cell surfaces, converting these antigens into complexes that can be recognised by other cells of the immune system to mount a response and destroy them.

For orchestrating these various processes efficiently and precisely, the dendritic cells are considered to be “conductors of the immune orchestra”.

In HITV, dendritic cells taken and processed from the patient’s own body are injected directly into the tumour, the “vaccination” process. As the cells need to be injected into the tumour, HITV is only suitable for solid tumours.

The tumour is subsequently subjected to image-guided intensity modulated radiotherapy and CTL (cytotoxic T-lymphocytes) injections to kill off cancer cells.

In a report entitled Clinical response of advanced cancer patients to cellular immunotherapy and intensity-modulated radiation therapy, published in the journal OncoImmunology in 2013, Dr Hasumi and co-authors wrote that “patients afflicted with advanced cancers were treated with the intratumoral injection of autologous immature dendritic cells (iDCs) followed by activated T-cell infusion and intensity-modulated radiation therapy (IMRT).

“A second round of iDCs and activated T cells was then administered to patients after the last radiation cycle. This complete regimen was repeated for new and recurring lesions after six weeks of follow-up.

Read more at http://www.thestar.com.my/lifestyle/health/2015/04/19/hitv-in-fight-against-cancer/#s7lzovDypPczEltZ.99

Source record here



HITV Lab is involved in cell-based biotechnology medical applications with special focus on Dendritic Cell-Based Immunotherapy for cancer. HITV Lab is committed to support an international collaboration in the FDA clinical trial of HITV Therapy in late-stage cancer patients led by the University of Maryland, USA.

FacebookTwitterGoogle Bookmarks